vs
Side-by-side financial comparison of Edwards Lifesciences (EW) and FLOWSERVE CORP (FLS). Click either name above to swap in a different company.
Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.1B, roughly 1.5× FLOWSERVE CORP). Edwards Lifesciences runs the higher net margin — 23.1% vs 7.6%, a 15.4% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs -6.7%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -3.9%).
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
The Flowserve Corporation is an American multinational corporation and one of the largest suppliers of industrial and environmental machinery such as pumps, valves, end face mechanical seals, automation, and services to the power, oil, gas, chemical and other industries. Headquartered in Irving, Texas, which is in the Dallas–Fort Worth Metroplex, Flowserve employs close to 16,000 employees in more than 50 countries. Flowserve sells products and offers aftermarket services to engineering and c...
EW vs FLS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $1.1B |
| Net Profit | $380.7M | $81.7M |
| Gross Margin | 78.0% | 35.6% |
| Operating Margin | 1.8% | 11.2% |
| Net Margin | 23.1% | 7.6% |
| Revenue YoY | 16.7% | -6.7% |
| Net Profit YoY | 6.8% | 10.5% |
| EPS (diluted) | $0.66 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.6B | $1.1B | ||
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.5B | $1.2B | ||
| Q1 25 | $1.4B | $1.1B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.4B | $1.1B | ||
| Q2 24 | $1.4B | $1.2B |
| Q1 26 | $380.7M | $81.7M | ||
| Q4 25 | $91.2M | $-29.0M | ||
| Q3 25 | $291.1M | $219.6M | ||
| Q2 25 | $333.2M | $81.8M | ||
| Q1 25 | $358.0M | $73.9M | ||
| Q4 24 | $385.6M | $77.5M | ||
| Q3 24 | $3.1B | $58.4M | ||
| Q2 24 | $366.3M | $72.6M |
| Q1 26 | 78.0% | 35.6% | ||
| Q4 25 | 78.1% | 34.8% | ||
| Q3 25 | 77.8% | 32.4% | ||
| Q2 25 | 77.5% | 34.2% | ||
| Q1 25 | 78.7% | 32.3% | ||
| Q4 24 | 78.9% | 31.5% | ||
| Q3 24 | 80.6% | 31.5% | ||
| Q2 24 | 79.9% | 31.6% |
| Q1 26 | 1.8% | 11.2% | ||
| Q4 25 | 9.6% | 3.5% | ||
| Q3 25 | 19.8% | 6.7% | ||
| Q2 25 | 26.8% | 12.3% | ||
| Q1 25 | 27.9% | 11.5% | ||
| Q4 24 | 22.6% | 10.6% | ||
| Q3 24 | 25.9% | 9.1% | ||
| Q2 24 | 26.8% | 10.5% |
| Q1 26 | 23.1% | 7.6% | ||
| Q4 25 | 5.8% | -2.4% | ||
| Q3 25 | 18.7% | 18.7% | ||
| Q2 25 | 21.7% | 6.9% | ||
| Q1 25 | 25.3% | 6.5% | ||
| Q4 24 | 27.8% | 6.6% | ||
| Q3 24 | 226.7% | 5.2% | ||
| Q2 24 | 26.7% | 6.3% |
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.16 | $-0.21 | ||
| Q3 25 | $0.50 | $1.67 | ||
| Q2 25 | $0.56 | $0.62 | ||
| Q1 25 | $0.61 | $0.56 | ||
| Q4 24 | $0.65 | $0.59 | ||
| Q3 24 | $5.13 | $0.44 | ||
| Q2 24 | $0.61 | $0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $792.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $2.3B |
| Total Assets | — | $5.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $792.4M | ||
| Q4 25 | $4.2B | $760.2M | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $3.9B | — | ||
| Q4 24 | $4.0B | $675.4M | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $2.0B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.3B | ||
| Q4 25 | $10.3B | $2.2B | ||
| Q3 25 | $10.2B | $2.3B | ||
| Q2 25 | $10.5B | $2.2B | ||
| Q1 25 | $10.1B | $2.1B | ||
| Q4 24 | $10.0B | $2.0B | ||
| Q3 24 | $9.5B | $2.1B | ||
| Q2 24 | $7.4B | $2.0B |
| Q1 26 | — | $5.7B | ||
| Q4 25 | $13.7B | $5.7B | ||
| Q3 25 | $13.3B | $5.8B | ||
| Q2 25 | $13.5B | $5.7B | ||
| Q1 25 | $13.0B | $5.5B | ||
| Q4 24 | $13.1B | $5.5B | ||
| Q3 24 | $13.0B | $5.3B | ||
| Q2 24 | $10.1B | $5.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
